A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia

New England Journal of Medicine

Volumn 337, Issue 12, 1997, Pages 809-815

  Rosenheck, Robert ^a,b,e   Cramer, Joyce ^a,b   Xu, Weichun ^c   Thomas, Jonathan ^c   Henderson, William ^c   Frisman, Linda ^a,b   Fye, Carol ^d   Charney, Dennis ^a,b  

^a West Haven   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Vet Aff Coop Studs Prog C   (United States)

^e VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT;

ADULT; AGRANULOCYTOSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG COST; FEMALE; HOSPITAL PATIENT; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; COSTS AND COST ANALYSIS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HALOPERIDOL; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; PATIENT COMPLIANCE; QUALITY OF LIFE; SCHIZOPHRENIA;

EID: 0030756517     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199709183371202     Document Type: Article

References (40)

1. Bromet EJ, Dew MA, Eaton W. Epidemiology of psychosis with special reference to schizophrenia. In: Tsuang MT, Tohen M, Zahner GEP, eds. Textbook in psychiatric epidemiology. New York: John Wiley, 1996:283-300.
2. Rupp A, Keith SJ. The costs of schizophrenia: assessing the burden. Psychiatr Clin North Am 1993;16:413-23.
3. Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr Bull 1993;19:287-302.
4. Kane JM, Honigfeld G, Singer J, Meltzer HY, Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45: 789-96.
5. Breier A, Buchanan RW, Kirkpatrick B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994;151:20-6.
6. Lieberman JA, Safferman AZ, Pollack S, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994;151:1744-52.
7. Pickar D, Ownen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH. Clinical and biologic response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiatry 1992;49:345-53.
8. Buchanan RW. Clozapine: efficacy and safety. Schizophr Bull 1995;21: 579-91.
9. Carpenter WT Jr, Conley RR, Buchanan RW, Breier A, Tamminga CA. Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry 1995;152:827-32.
10. Breier A, Buchanan RW, Irish D, Carpenter WT Jr. Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Hosp Community Psychiatry 1993;44:1145-9.
11. Meltzer HY, Burnett S, Bastani B, Ramirez LF. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990;41:892-7.
12. Meltzer HY. Clozapine: is another view valid? Am J Psychiatry 1995; 152:821-5.
13. Marder SR. Adverse effects of clozapine. J Clin Psychiatry Monogr Ser 1996;14:11-2.
14. Griffith RW, Saameli J. Clozapine and agranulocytosis. Lancet 1975; 2:657.
15. Alvir JMJ, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993;329:162-7
16. Meltzer HY, Cola PA. The pharmacoeconomics of clozapine: a review. J Clin Psychiatry 1994;55:Suppl B:161-5.
17. Revicki DA, Luce BR, Weschler JM, Brown RE, Adler MA. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Community Psychiatry 1990;41:850-4.
18. Meltzer HY, Cola P, Way L, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993;150:1630-8.
19. Reid WH, Mason M, Toprac M. Savings in hospital bed-days related to treatment with clozapine. Hosp Community Psychiatry 1994;45:261-4.
20. Essock SM, Hargreaves WA, Covell NH, Goethe J. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull 1996;32:683-97.
21. Diagnostic and statistical manual of mental disorders: DSM-III-R. 3rd ed., rev. Washington, D.C.: American Psychiatric Press, 1987.
22. Spitzer RS, Williams JBW, Gibbon M, First MB. User's guide for the Structured Clinical Interview for DSM-III-R: SCID. Washington, D.C.: American Psychiatric Press, 1990.
23. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
24. Guy W. Clinical global impression. In: Guy W, ed. ECDEU assessment manual for psychopharmacology. Rockville, Md.: National Institute of Mental Health, 1976:218-21. (DHEW publication no. ADM 76-338.)
25. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
26. Heinrichs DW, Hanlon ET, Carpenter WT Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10:388-98.
27. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-6.
28. Guy W. Abnormal involuntary movements. In: Guy W, ed. ECDEU assessment manual for psychopharmacology. Rockville, Md.: National Institute of Mental Health, 1976. (DHEW publication no. ADM 76-338.)
29. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-9.
30. Cicchetti DV, Showalter D, Rosenheck RA. A new method for assessing interexaminer agreement when multiple ratings are made on a single subject: applications to the assessment of neuropsychiatrie symptomatology. Psychiatry Res (in press).
31. Rosenheck RA, Neale M, Leaf P, Milstein R, Frisman L. Multisite experimental cost study of intensive psychiatric community care. Schizophr Bull 1995;21:129-40.
32. Rosenheck R, Frisman L, Neale M. Estimating the capital component of mental health care costs in the public sector. Admin Policy Mental Health 1994;21:493-509.
33. Rosenheck RA, Neale M, Frisman L. Issues in estimating the cost of innovative mental health programs. Psychiatr Q 1995;66:9-31.
34. Comparison of costs and outcomes of matched pairs of VAMCs and their university affiliates. Washington, D.C.: Office of the Inspector General, 1992.
35. Frisman LK, Rosenheck RA. How transfer payments are treated in cost-effectiveness and cost-benefit analysis. Adm Policy Mental Health 1996;23:533-46.
36. Schobel BD. Administrative expenses under OASDI. Soc Secur Bull 1981;44:21-8.
37. Department of Justice Office of Justice Programs, Bureau of Justice Statistics. Justice expenditures and employment in the United States, 1988. Washington, D.C.: Government Printing Office, 1991. (Publication no. NCJ-125619.)
38. Department of Justice Office of Justice Programs, Bureau of Justice Statistics. Sourcebook of criminal justice statistics - 1990. Washington, D.C.: Government Printing Office, 1991. (Publication no. NCJ-130580.)
39. Tessler R, Gamache G. Continuity of care, residence and family burden in Ohio. Milbank Q 1994;72:149-69.
40. Gibbons RD, Hedeker D, Elkin I, et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data: application to the NIMH Treatment of Depression Collaborative Research Program dataset. Arch Gen Psychiatry 1993;50:739-50.